Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM (1999) The biology of chronic myeloid leukemia. N Engl J Med 341:164–172

Article  CAS  PubMed  Google Scholar 

Brück O, Blom S, Dufva O, Turkki R, Chheda H, Ribeiro A et al (2018) Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia 32:1643–1656

Article  PubMed  Google Scholar 

Kondĕlková K, Vokurková D, Krejsek J, Borská L, Fiala Z, Ctirad A (2010) Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders. Acta Med 53:73–77

Google Scholar 

D’Arena G, Vitale C, Coscia M, Festa A, Di Minno NMD, De Feo V et al (2017) Regulatory T cells and their prognostic relevance in hematologic malignancies. J Immunol Res 2017:1832968

Article  PubMed  PubMed Central  Google Scholar 

Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24:207–212

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boussiotis VA (2016) Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 375:1767–1778

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mumprecht S, Schürch C, Schwaller J, Solenthaler M, Ochsenbein AF (2009) Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 114:1528–1536

Article  CAS  PubMed  Google Scholar 

Goldman JM (2007) How I treat chronic myeloid leukemia in the imatinib era. Blood 110:2828–2837

Article  CAS  PubMed  Google Scholar 

Bachy E, Bernaud J, Roy P, Rigal D, Nicolini FE (2011) Quantitative and functional analyses of CD4+CD25+FoxP3+ regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate. Br J Haematol 153:139–143

Article  CAS  PubMed  Google Scholar 

Larmonier N, Janikashvili N, LaCasse CJ, Larmonier CB, Cantrell J, Situ E et al (1950) Imatinib mesylate inhibits CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABLnegative tumors. J Immunol Baltim Md 2008(181):6955–6963

Google Scholar 

Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Götz M et al (2009) Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells. Br J Haematol 144:195–205

Article  CAS  PubMed  Google Scholar 

Lee MY, Park CJ, Cho YU, You E, Jang S, Seol CA et al (2020) Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication. Cancer Immunol Immunother 69:2223–2232

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP et al (2017) CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood 129:1166–1176

Article  CAS  PubMed  Google Scholar 

Chikkodi SV, Malhotra P, Naseem S, Khadwal A, Prakash G, Sahu KK et al (2015) Factors affecting early molecular response in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 15(Suppl):S114-119

Article  PubMed  Google Scholar 

Zahran AM, Badrawy H, Ibrahim A (2014) Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients. Int J Clin Oncol 19:753–760

Article  CAS  PubMed  Google Scholar 

Rojas JM, Wang L, Owen S, Knight K, Watmough SJ, Clark RE (2010) Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive. Exp Hematol 38:1209–1218

Article  CAS  PubMed  Google Scholar 

Hus I, Tabarkiewicz J, Lewandowska M, Wasiak M, Wdowiak P, Kusz M et al (2011) Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Folia Histochem Cytobiol 49:153–160

Article  CAS  PubMed  Google Scholar 

Hinterbrandner M, Rubino V, Stoll C, Forster S, Schnüriger N, Radpour R et al (2021) Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells. JCI Insight 6:e151797

Article  PubMed  PubMed Central  Google Scholar 

Tanaka A, Nishikawa H, Noguchi S, Sugiyama D, Morikawa H, Takeuchi Y et al (2020) Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. J Exp Med 217:e20191009

Article  PubMed  Google Scholar 

Fujioka Y, Sugiyama D, Matsumura I, Minami Y, Miura M, Atsuta Y et al (2021) Regulatory T cell as a biomarker of treatment-free remission in patients with chronic myeloid leukemia. Cancers 13:5904

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tan J, Chen S, Lu Y, Yao D, Xu L, Zhang Y et al (2017) Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia. Chin J Cancer Res 29:463–470

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee MY, Park C, Cho YU, You E, Jang S, Seol CA et al (2017) Expression levels of PD-1 on CD8+ T cells in chronic myeloid leukemia with and without BCR-ABL1 kinase mutation. Blood 130:4178–4178

Google Scholar 

Christiansson L, Söderlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B et al (2013) Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/PRogrammed death receptor 1, and soluble CD25 in sokal high risk chronic myeloid leukemia. PLoS ONE 8:e55818

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holyoake TL, Vetrie D (2017) The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood 129:1595–1606

Article  CAS  PubMed  Google Scholar 

Sharma P, Sachdeva MUS, Naseem S, Sreedharanunni S, Das R, Malhotra P et al (2022) Identification of peripheral blood CD26+ leukemic stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia. Int J Lab Hematol 44:518–523

Article  PubMed  Google Scholar 

Riether C, Gschwend T, Huguenin AL, Schürch CM, Ochsenbein AF (2015) Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells. Leukemia 29:1781–1785

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zeidan AM, Wang V, Radich JP, Bewersdorf JP, Bhatt VR, Sharon E et al (2020) Blast MRD CML 1 Trial: Blockade of PD-1 added to standard therapy to target measurable residual disease (MRD) in chronic myeloid leukemia (CML)- a phase II study of adding the anti-PD-1 pembrolizumab to tyrosine kinase inhibitors in patients with chronic myeloid leukemia and persistently detectable minimal residual disease: a trial of the ECOG-ACRIN cancer research group (EA9171). Blood 136:1–1

Article  Google Scholar 

Anand MS, Varma N, Varma S, Rana KS, Malhotra P (2012) Cytogenetic & molecular analyses in adult chronic myelogenous leukaemia patients in north India. Indian J Med Res 135:42–48

Article  PubMed  PubMed Central  Google Scholar 

Atallah E, Schiffer CA (2020) Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? Haematologica 105:2738–2745

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goni D, Jain A, Singh C, Jindal N, Nampoothiri R, Jandial A et al (2023) Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study. Indian J Med Res 157:87–91

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yanamandra U, Malhotra P (2019) CML in India: Are We There Yet? Indian J Hematol Blood Transfus 35:1–2